Lisbon 2017 Delegate Registration Programme Exhibition Virtual Exhibition Satellites OneWorld Travel Discount
escrs app advert


Search Title by author or title

eyeWatch, an innovative adjustable GDD for the treatment of glaucoma: report on the first clinical results

Poster Details

First Author: A.Mermoud SWITZERLAND

Co Author(s):    A. Villamarin   S. Roy   N. Stergiopulos              

Abstract Details


To report the very first surgical cases of a continuously adjustable glaucoma drainage device (GDD) in glaucoma surgery using seton tubes.


Clinique de Montchoisi, Lausanne, Switzerland


Mono-centric clinical study. After placement of a classical seton tube, the eyeWatch was inserted into the anterior chamber through a 25G channel. After securing the implant onto the sclera, the device was then connected to the seton tube. The implant was covered by a scleral patch. A magnetic system enables the opening or closing of the system to provide an adjustment of the intraocular pressure (IOP). During the postoperative follow-up, the eyeWatch system can be used to adjust the IOP preventing early postoperative hypotony. The main outcomes were mean IOP, mean number of antiglaucoma medications and postoperative complications


18 patients were operated, with a mean follow-up of 6.6�Â�±3.9 months. The mean baseline IOP was 26.1�Â�±10.6 mmHg and the number of antiglaucoma medications (AGM) was 2.9�Â�±0.9. The mean postoperative pressure after 1 month was 13.8�Â�±5.3 mmHg and AGM was 0.6�Â�±0.9, and after 6 months IOP was 12.5�Â�±3.9 mmHg and AGM was 0.9�Â�±0.8. The IOP was well controlled throughout the entire follow-up period and no cases of effective hypotony were recorded.


The eyeWatch can easily be implanted during glaucoma surgery using seton tubes. This system better addresses the hypotony phase observed after insertion of tubes enabling a proper IOP control. Finally, the portion of the implant placed in the anterior chamber has a fixed angle to prevent corneal touch and is of a much smaller diameter compared to the classic seton tubes what could prevent endothelial cells alteration leading to late corneal decompensation.

Financial Disclosure:

has significant investment interest in a company producing, developing or supplying product or procedure presented, research is funded, fully or partially, by a company producing, developing or supplying the product or procedure presented, is employed by a for-profit company with an interest in the subject of the presentation

Back to Poster listing